Biogen Patent-Cliff Exposure & CMS Drug Spending Portfolio
Biogen (Cambridge, MA): 13 reconciled FDA prescription therapies, $1.29B 2024 CMS Part D & Medicaid spend, and $30,833 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Cambridge, MA |
| Reconciled FDA Portfolio Therapies | 13 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2033-01-01 |
| 2024 CMS Total Public Spend | $1.29B |
| 2024 Medicare Part D Spend | $821.9M |
| 2024 Medicaid Spend | $466.6M |
| California HCAI SB 17 Filings | Specialty launch notice ($30,833 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.